Study participants | Number examined (N) | Anti-Toxoplasma gondii seropositivity (n/N; %) | χ 2 value | p value (CI 95 %) |
---|---|---|---|---|
Pregnant women | 125 | 64 (51.2) | ||
Age groups | ||||
16–20 | 4 | 4 (100) | 3.94 | <0.05* |
21–30 | 57 | 30 (52.6) | 0.08 | 0.76 |
31–40 | 58 | 27 (46.6) | 0.94 | 0.33 |
41–44 | 6 | 3 (50.0) | 0.04 | 0.95 |
Stage of pregnancy | ||||
1st trimester | 7 | 4 (57.1) | 0.11 | 0.74 |
2nd trimester | 38 | 22 (57.8) | 0.98 | 0.32 |
3rd trimester | 80 | 38 (47.5) | 1.21 | 0.26 |
Gravida status of women | ||||
Primigravids | 49 | 17 (34.7) | 8.79 | 0.003* |
Multigravids | 76 | 47 (61.8) | ||
HIV-seropositive persons | 125 | 72 (57.6) | ||
Age groups | ||||
15–24 | 4 | 1 (25.0) | 1.79 | 0.17 |
25–34 | 27 | 16 (59.3) | 0.04 | 0.84 |
35–44 | 51 | 26 (50.9) | 1.54 | 0.21 |
45–54 | 30 | 20 (66.7) | 1.32 | 0.25 |
55–64 | 12 | 8 (66.7) | 0.44 | 0.50 |
65–68 | 1 | 1 (100) | 0.74 | 0.389 |
Gender | ||||
Male | 54 | 32 (59.2) | 0.10 | 0.74 |
Female | 71 | 40 (56.3) | ||
CD4+ T cell count cell/mm3 | ||||
<200 | 9 | 6 (66.7) | 0.32 | 0.56 |
200 ≥ CD4+ ≤ 500 | 64 | 38 (59.4) | 0.16 | 0.68 |
>500 | 52 | 28 (53.8) | 0.52 | 0.47 |
Children <5 years of age | 200 | 117 (58.5) | ||
Age groups | ||||
0–6 months | 27 | 6 (22.2) | 26.46 | <0.001* |
6–12 months | 30 | 9 (30.0) | 11.80 | <0.001* |
1–3 years | 69 | 48 (69.6) | 5.31 | 0.02* |
3 years > X < 5 years | 74 | 53 (71.6) | 7.32 | <0.001* |
Gender | ||||
Male | 109 | 68 (62.4) | 1.18 | 0.27 |
Female | 91 | 49 (53.8) |